Flash Finance

Akums Drugs and Pharmaceuticals LimitedAKUMSCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 13 quarters of data
Consolidated Standalone
₹731.45
MCap ₹11,199 Cr · P/E 100.5
Akums Drugs and Pharmaceuticals Limited — Stock analysis & AI research Akums Drugs and Pharmaceuticals Limited — Seasonality — best & worst months Akums Drugs and Pharmaceuticals Limited — Technical indicators & charts Akums Drugs and Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Akums Drugs and Pharmaceuticals Limited — Live exchange announcements
📋 High Promoter Holding Stocks 📈 SuperTrend Bearish Signal📈 20-Day Breakdown Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹392 Cr
Sales · Jun 2026
+18.0% YoY
₹49 Cr
Operating Profit · Jun 2026
+10.0% YoY
12.4%
OPM % · Jun 2026
-6.8% YoY
₹45 Cr
Net Profit · Jun 2026
-0.1% YoY
₹2.93
EPS · Jun 2026
+0.0% YoY

📝 Akums Drugs and Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Akums Drugs and Pharmaceuticals Limited reported revenue of ₹392 crore for the quarter ended June 2026 (Q1 FY27), up 18.0% from ₹332 crore in the same quarter last year, and up 16.1% sequentially over the March 2026 quarter.

Net profit fell 0.1% year-on-year to ₹45 crore, from ₹45 crore. Earnings per share (EPS) came in at ₹2.93.

Operating profit stood at ₹49 crore — an operating margin (OPM) of 12.4%, compared with 13.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Akums Drugs and Pharmaceuticals Limited posted revenue of ₹1,348 crore, a growth of 2.8% over FY25, with a net profit of ₹111 crore (down 30.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,408 crore with a net profit of ₹111 crore.

Valuation snapshot

At the current price of ₹731.45, AKUMS has a market capitalisation of ₹11,199 crore and a trailing P/E of about 100.5.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 75.26%, foreign institutional investors (FIIs) 1.38%, domestic institutional investors (DIIs) 14.36%, public shareholders 6.29% of Akums Drugs and Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹11,199 Cr
Current Price ?
₹731.5
P/E ?
100.51above ind
Industry P/E ?
37.20
P/B ?
4.61
P/S ?
7.95
P/FCF ?
-91.05
Enterprise Value ?
₹11,258 Cr
EV/EBITDA ?
110.30
PEG ?
N/A
Earnings Yield ?
0.5%
Dividend Yield ?
0.13%
Profitability & Returns
Sales (TTM) ?
₹1,408 Cr
OPM ?
7.2%
Profit after tax (TTM) ?
₹111 Cr
EPS (TTM) ?
₹7.28
ROCE ?
7.0%
ROE ?
4.6%
ROA ?
4.0%
Growth
Sales — latest qtr ?
₹392 Cr
PAT — latest qtr ?
₹45 Cr
YoY qtr sales growth ?
18.0%
YoY qtr profit growth ?
-0.1%
Sales growth (3y) ?
2%
Sales growth (5y) ?
10%
Profit growth (3y) ?
-20%
Profit growth (5y) ?
1%
Financial Health
Debt ?
₹59 Cr
Debt to Equity ?
0.02
Interest Coverage ?
5.0
Current Ratio ?
N/A
Ownership
Promoter holding ?
75.26%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
10.0%
Return 6 months ?
34.0%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 316447383298317328337329332309369338392 +18.0% +16.1%
Operating Profit -1878932-61444334184417251249 +10.0% +304.2%
Other Income 2042525263234322927302526 -8.6% +4.4%
Interest 4555642332232 -14.9% -17.5%
Depreciation 78899911101011121213 +24.9% +6.6%
Profit Before Tax -1788143-49546255376031362259 -0.3% +169.7%
Net Profit -1905329-58425041284523281545 -0.1% +198.9%
EPS -13.263.692.05-4.052.933.202.691.752.931.531.840.972.93 +0.0% +202.1%
OPM % -59.2% 19.9% 8.4% -20.5% 13.8% 13.1% 10.1% 5.5% 13.3% 5.5% 6.7% 3.6% 12.4% -6.8% +244.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,312 Cr ₹1,348 Cr ₹1,408 Cr +2.8%
Operating Profit ₹139 Cr ₹98 Cr ₹102 Cr -29.6%
OPM % 10.57% 7.24% 7.25% -31.5%
NPM % 12.28% 8.27% 7.91% -32.7%
Other Income ₹124 Cr ₹110 Cr ₹108 Cr -11.1%
Depreciation ₹39 Cr ₹45 Cr ₹48 Cr +15.4%
Interest ₹16 Cr ₹10 Cr ₹10 Cr -32.6%
EBIT ₹100 Cr ₹53 Cr ₹54 Cr -47.2%
PBT ₹208 Cr ₹149 Cr ₹148 Cr -28.6%
Tax ₹26 Cr ₹30 Cr ₹30 Cr +15.4%
Net Profit ₹161 Cr ₹111 Cr ₹111 Cr -30.8%
EPS ₹10.57 ₹7.27 ₹7.27 -31.2%
Material Cost ₹408 Cr ₹618 Cr ₹679 Cr +51.5%
Employee Cost ₹98 Cr ₹160 Cr ₹168 Cr +64.2%
Extraordinary Items — ₹-4 Cr ₹-4 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 29293131 +0.0%
Reserves 2831152,2752,397 +5.4%
Borrowings 1462674659 +28.3%
Other Liabilities 1,4371,684333326 -2.1%
Total Liabilities 1,8942,0952,6852,812 +4.7%
Fixed Assets 272317356426 +19.7%
CWIP 1695752 -8.8%
Investments 139139366366 +0.0%
Other Assets 1,4661,6311,9061,969 +3.3%
Total Assets 1,8942,0952,6852,812 +4.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 9424891-2 -102.2%
Cash from Investing Activity -202-165-459-25 +94.6%
Cash from Financing Activity 90-21375-3 -100.8%
Net Cash Flow -18628-30 -475.0%
Free Cash Flow -9177-3-123 -4000.0%
CFO/OP 51%-225%104%35% -66.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 73595759 +3.5%
Inventory Days 916892101 +9.8%
Days Payable 826910089 -11.0%
Cash Conversion Cycle 82584971 +44.9%
Working Capital Days 4-114767 +42.6%
ROCE % 79%-15%16%7% -56.2%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 75.26%75.26%75.26%75.26% +0.0%
FIIs 4.24%2.27%1.14%1.38% +21.1%
DIIs 8.85%9.28%14.41%14.36% -0.3%
Public 8.92%10.46%6.45%6.29% -2.5%
Others 2.73%2.73%2.73%2.73% +0.0%
No. of Shareholders 69,42475,36576,86972,589 -5.6%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Akums Drugs and Pharmaceuticals Limited's revenue in Q1 FY27?
Akums Drugs and Pharmaceuticals Limited reported revenue of ₹392 crore for the quarter ended June 2026 (Q1 FY27), up 18.0% from ₹332 crore in the same quarter last year, and up 16.1% sequentially over the March 2026 quarter.
What was Akums Drugs and Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit fell 0.1% year-on-year to ₹45 crore, from ₹45 crore. Earnings per share (EPS) came in at ₹2.93.
What is AKUMS's market capitalisation and P/E ratio?
At the current price of ₹731.45, AKUMS has a market capitalisation of ₹11,199 crore and a trailing P/E of about 100.5.
Who owns Akums Drugs and Pharmaceuticals Limited? (shareholding pattern)
As of Mar 2026, promoters held 75.26%, foreign institutional investors (FIIs) 1.38%, domestic institutional investors (DIIs) 14.36%, public shareholders 6.29% of Akums Drugs and Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI